| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoma, Osteoid | 15 | 2024 | 94 | 2.670 |
Why?
|
| Bone Neoplasms | 23 | 2024 | 2565 | 1.730 |
Why?
|
| Radiology | 15 | 2024 | 2104 | 1.680 |
Why?
|
| Radiology Department, Hospital | 6 | 2017 | 409 | 1.140 |
Why?
|
| Chordoma | 5 | 2017 | 349 | 1.080 |
Why?
|
| Radiology Information Systems | 8 | 2018 | 533 | 1.080 |
Why?
|
| Lumbar Vertebrae | 8 | 2020 | 1889 | 0.960 |
Why?
|
| Musculoskeletal System | 3 | 2016 | 188 | 0.870 |
Why?
|
| Radiography, Interventional | 7 | 2024 | 1131 | 0.820 |
Why?
|
| Spinal Neoplasms | 4 | 2017 | 715 | 0.820 |
Why?
|
| Periodicals as Topic | 5 | 2016 | 1470 | 0.810 |
Why?
|
| Gaucher Disease | 4 | 2014 | 110 | 0.790 |
Why?
|
| Catheter Ablation | 12 | 2016 | 2780 | 0.710 |
Why?
|
| Diagnostic Imaging | 9 | 2019 | 3538 | 0.650 |
Why?
|
| Pyrrolidines | 3 | 2014 | 341 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 26 | 2024 | 20776 | 0.540 |
Why?
|
| Lipomatosis | 1 | 2016 | 112 | 0.510 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2016 | 119 | 0.500 |
Why?
|
| Publishing | 2 | 2016 | 837 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2019 | 36854 | 0.480 |
Why?
|
| Medical Records | 2 | 2011 | 1411 | 0.480 |
Why?
|
| Bone Demineralization, Pathologic | 1 | 2014 | 7 | 0.470 |
Why?
|
| Pelvic Neoplasms | 1 | 2016 | 250 | 0.470 |
Why?
|
| Spinal Diseases | 3 | 2018 | 563 | 0.450 |
Why?
|
| Extremities | 4 | 2013 | 870 | 0.440 |
Why?
|
| Radiography | 8 | 2021 | 6991 | 0.440 |
Why?
|
| Hospital Information Systems | 1 | 2015 | 394 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 592 | 0.410 |
Why?
|
| Workflow | 1 | 2017 | 859 | 0.400 |
Why?
|
| Child Abuse | 1 | 2021 | 1091 | 0.390 |
Why?
|
| Automation | 2 | 2011 | 589 | 0.390 |
Why?
|
| Tibia | 3 | 2014 | 1076 | 0.380 |
Why?
|
| Lumbosacral Region | 4 | 2017 | 294 | 0.370 |
Why?
|
| Medical Order Entry Systems | 5 | 2016 | 523 | 0.370 |
Why?
|
| Thoracoscopy | 1 | 2011 | 186 | 0.360 |
Why?
|
| Waiting Lists | 1 | 2015 | 779 | 0.350 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 156 | 0.350 |
Why?
|
| Thoracic Vertebrae | 2 | 2011 | 614 | 0.350 |
Why?
|
| Spine | 2 | 2017 | 1141 | 0.350 |
Why?
|
| Curriculum | 1 | 2024 | 3782 | 0.340 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2012 | 195 | 0.340 |
Why?
|
| Editorial Policies | 1 | 2014 | 460 | 0.340 |
Why?
|
| Spinal Fractures | 1 | 2016 | 712 | 0.340 |
Why?
|
| Fluoroscopy | 2 | 2010 | 947 | 0.330 |
Why?
|
| Low Back Pain | 1 | 2018 | 990 | 0.330 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 2784 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 6 | 2016 | 2182 | 0.310 |
Why?
|
| Sacrum | 4 | 2016 | 275 | 0.310 |
Why?
|
| Durapatite | 1 | 2010 | 167 | 0.310 |
Why?
|
| Decision Support Systems, Clinical | 5 | 2016 | 1178 | 0.300 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 3726 | 0.300 |
Why?
|
| Cosmetic Techniques | 1 | 2010 | 150 | 0.290 |
Why?
|
| Lipodystrophy, Congenital Generalized | 1 | 2007 | 10 | 0.290 |
Why?
|
| Electronic Mail | 1 | 2009 | 215 | 0.290 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 877 | 0.280 |
Why?
|
| Radiography, Thoracic | 2 | 2012 | 1321 | 0.280 |
Why?
|
| Cartilage Diseases | 1 | 2008 | 160 | 0.270 |
Why?
|
| Connective Tissue Diseases | 1 | 2010 | 285 | 0.270 |
Why?
|
| Biopsy | 5 | 2019 | 6805 | 0.270 |
Why?
|
| Bone Density | 3 | 2014 | 3574 | 0.270 |
Why?
|
| Arm Bones | 1 | 2006 | 4 | 0.270 |
Why?
|
| Internet | 2 | 2010 | 3112 | 0.270 |
Why?
|
| User-Computer Interface | 4 | 2018 | 1406 | 0.260 |
Why?
|
| Musculoskeletal Diseases | 1 | 2011 | 599 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2016 | 9442 | 0.250 |
Why?
|
| Diabetic Foot | 1 | 2009 | 383 | 0.240 |
Why?
|
| Peer Review, Health Care | 2 | 2016 | 73 | 0.230 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2005 | 146 | 0.230 |
Why?
|
| Scapula | 1 | 2006 | 175 | 0.230 |
Why?
|
| Humans | 90 | 2024 | 768970 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 1892 | 0.220 |
Why?
|
| Osteomyelitis | 2 | 2020 | 408 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1970 | 0.200 |
Why?
|
| Anti-Anxiety Agents | 4 | 2007 | 405 | 0.200 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 192 | 0.190 |
Why?
|
| Outpatients | 4 | 2017 | 1603 | 0.190 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 1005 | 0.190 |
Why?
|
| Referral and Consultation | 5 | 2016 | 3628 | 0.190 |
Why?
|
| Glucosylceramidase | 1 | 2002 | 125 | 0.190 |
Why?
|
| Cartilage, Articular | 1 | 2008 | 1104 | 0.180 |
Why?
|
| Calcinosis | 1 | 2010 | 1479 | 0.180 |
Why?
|
| Models, Statistical | 1 | 2015 | 5110 | 0.180 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 3438 | 0.180 |
Why?
|
| Biopsy, Needle | 3 | 2015 | 1626 | 0.180 |
Why?
|
| Sarcoma | 4 | 2016 | 1806 | 0.180 |
Why?
|
| Discitis | 1 | 2020 | 45 | 0.170 |
Why?
|
| Adult | 36 | 2019 | 223851 | 0.170 |
Why?
|
| Male | 49 | 2024 | 365203 | 0.160 |
Why?
|
| Osteoblastoma | 1 | 2019 | 24 | 0.160 |
Why?
|
| Clinical Competence | 3 | 2024 | 4860 | 0.160 |
Why?
|
| Diagnostic Errors | 2 | 2016 | 1281 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2015 | 1166 | 0.150 |
Why?
|
| Middle Aged | 34 | 2018 | 223737 | 0.150 |
Why?
|
| Femoral Fractures | 1 | 2022 | 376 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2024 | 2664 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 14752 | 0.140 |
Why?
|
| Subarachnoid Space | 1 | 2017 | 79 | 0.140 |
Why?
|
| Female | 43 | 2024 | 397515 | 0.140 |
Why?
|
| Retrospective Studies | 15 | 2024 | 81903 | 0.140 |
Why?
|
| Syringomyelia | 1 | 2017 | 67 | 0.140 |
Why?
|
| Carcinoma, Giant Cell | 1 | 2016 | 5 | 0.140 |
Why?
|
| Spondylosis | 1 | 2017 | 85 | 0.140 |
Why?
|
| Clavicle | 1 | 2019 | 224 | 0.140 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2017 | 197 | 0.130 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2017 | 160 | 0.130 |
Why?
|
| Hospitalization | 1 | 2015 | 10847 | 0.120 |
Why?
|
| Femur Head Necrosis | 1 | 2016 | 133 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 1134 | 0.120 |
Why?
|
| Spiro Compounds | 1 | 2014 | 69 | 0.120 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2016 | 411 | 0.120 |
Why?
|
| Forecasting | 1 | 2024 | 2945 | 0.120 |
Why?
|
| Fractures, Bone | 2 | 2019 | 2063 | 0.120 |
Why?
|
| Receptors, Opioid | 1 | 2014 | 145 | 0.120 |
Why?
|
| Photons | 2 | 2016 | 595 | 0.120 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 236 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2022 | 1006 | 0.110 |
Why?
|
| Femur | 3 | 2022 | 1321 | 0.110 |
Why?
|
| Child | 14 | 2024 | 80960 | 0.110 |
Why?
|
| Adolescent | 14 | 2024 | 89244 | 0.110 |
Why?
|
| Patient Positioning | 2 | 2016 | 332 | 0.110 |
Why?
|
| Aged, 80 and over | 11 | 2016 | 59739 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2017 | 443 | 0.110 |
Why?
|
| Industry | 1 | 2015 | 362 | 0.110 |
Why?
|
| Employee Performance Appraisal | 1 | 2013 | 86 | 0.110 |
Why?
|
| Bone and Bones | 2 | 2016 | 2590 | 0.110 |
Why?
|
| Young Adult | 13 | 2024 | 60131 | 0.100 |
Why?
|
| Osteotomy | 1 | 1998 | 838 | 0.100 |
Why?
|
| Aged | 20 | 2022 | 171786 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8055 | 0.100 |
Why?
|
| Joint Diseases | 1 | 2016 | 461 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2017 | 610 | 0.100 |
Why?
|
| Knee Joint | 2 | 2022 | 1685 | 0.100 |
Why?
|
| Back Pain | 2 | 2016 | 548 | 0.100 |
Why?
|
| Child, Preschool | 8 | 2024 | 42683 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2017 | 15889 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2009 | 4879 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2014 | 4040 | 0.100 |
Why?
|
| Chondroblastoma | 2 | 2009 | 47 | 0.090 |
Why?
|
| Treatment Outcome | 11 | 2017 | 65480 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 2422 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2016 | 2280 | 0.090 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2022 | 1405 | 0.090 |
Why?
|
| Heart Rate | 1 | 2003 | 4217 | 0.090 |
Why?
|
| Current Procedural Terminology | 1 | 2011 | 101 | 0.090 |
Why?
|
| Public Opinion | 1 | 2014 | 486 | 0.090 |
Why?
|
| Retreatment | 1 | 2012 | 600 | 0.090 |
Why?
|
| Efficiency | 1 | 2013 | 480 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2010 | 54 | 0.090 |
Why?
|
| Glucosyltransferases | 1 | 2010 | 94 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 236 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 454 | 0.090 |
Why?
|
| Macrocyclic Compounds | 1 | 2010 | 67 | 0.090 |
Why?
|
| Viscera | 1 | 2010 | 138 | 0.090 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 13021 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 848 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 328 | 0.080 |
Why?
|
| Small Molecule Libraries | 1 | 2014 | 742 | 0.080 |
Why?
|
| Algorithms | 2 | 2012 | 14201 | 0.080 |
Why?
|
| Facial Pain | 1 | 2010 | 122 | 0.080 |
Why?
|
| Injections, Epidural | 1 | 2010 | 203 | 0.080 |
Why?
|
| Osteitis Fibrosa Cystica | 1 | 2008 | 11 | 0.080 |
Why?
|
| Zygapophyseal Joint | 1 | 2010 | 129 | 0.080 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2010 | 308 | 0.080 |
Why?
|
| Boston | 3 | 2015 | 9377 | 0.080 |
Why?
|
| United States | 6 | 2024 | 73186 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 20245 | 0.070 |
Why?
|
| Communication | 2 | 2014 | 3908 | 0.070 |
Why?
|
| Notochord | 1 | 2007 | 37 | 0.070 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 1758 | 0.070 |
Why?
|
| Imidazoles | 2 | 2004 | 1169 | 0.070 |
Why?
|
| Ilium | 1 | 2008 | 155 | 0.070 |
Why?
|
| Neoplasms | 1 | 2016 | 22389 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2018 | 54962 | 0.070 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2008 | 124 | 0.070 |
Why?
|
| Injections, Intra-Articular | 1 | 2008 | 288 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2011 | 641 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2569 | 0.070 |
Why?
|
| Bone Cements | 1 | 2008 | 327 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 39394 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2017 | 2701 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 7460 | 0.070 |
Why?
|
| Acetylene | 1 | 2006 | 8 | 0.070 |
Why?
|
| Sarcoidosis | 1 | 2012 | 535 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 752 | 0.070 |
Why?
|
| Infant | 3 | 2024 | 36556 | 0.070 |
Why?
|
| Internationality | 1 | 2012 | 1008 | 0.070 |
Why?
|
| Dominance-Subordination | 1 | 2005 | 26 | 0.070 |
Why?
|
| Chondroma | 2 | 2005 | 53 | 0.060 |
Why?
|
| Femoral Neoplasms | 2 | 2003 | 85 | 0.060 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2010 | 614 | 0.060 |
Why?
|
| Structure-Activity Relationship | 5 | 2014 | 3057 | 0.060 |
Why?
|
| Competitive Behavior | 1 | 2005 | 78 | 0.060 |
Why?
|
| Tourniquets | 1 | 2006 | 111 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1252 | 0.060 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 1232 | 0.060 |
Why?
|
| Documentation | 1 | 2011 | 917 | 0.060 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2006 | 171 | 0.060 |
Why?
|
| Calcaneus | 1 | 2006 | 144 | 0.060 |
Why?
|
| Acetabulum | 1 | 2008 | 543 | 0.060 |
Why?
|
| Malpractice | 1 | 2009 | 561 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2241 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2015 | 6291 | 0.060 |
Why?
|
| Health Services Research | 1 | 2011 | 1818 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2005 | 575 | 0.060 |
Why?
|
| Software | 2 | 2010 | 4479 | 0.060 |
Why?
|
| Time Factors | 3 | 2016 | 40261 | 0.050 |
Why?
|
| Quinazolines | 1 | 2010 | 1373 | 0.050 |
Why?
|
| Amides | 1 | 2006 | 452 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 14794 | 0.050 |
Why?
|
| Receptors, Corticotropin | 1 | 2003 | 24 | 0.050 |
Why?
|
| Artifacts | 1 | 2012 | 1942 | 0.050 |
Why?
|
| Thiadiazoles | 1 | 2003 | 63 | 0.050 |
Why?
|
| alpha-MSH | 1 | 2003 | 71 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2005 | 963 | 0.050 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2002 | 86 | 0.050 |
Why?
|
| Medical Errors | 1 | 2010 | 1262 | 0.050 |
Why?
|
| Necrosis | 1 | 2006 | 1620 | 0.050 |
Why?
|
| Prevalence | 3 | 2016 | 15879 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 1703 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 4926 | 0.050 |
Why?
|
| Bone Nails | 1 | 2022 | 221 | 0.040 |
Why?
|
| Observer Variation | 2 | 2018 | 2623 | 0.040 |
Why?
|
| Enzymes | 1 | 2002 | 254 | 0.040 |
Why?
|
| Calcitriol | 1 | 2002 | 303 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2017 | 4748 | 0.040 |
Why?
|
| Splenectomy | 1 | 2002 | 392 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 13318 | 0.040 |
Why?
|
| Massachusetts | 3 | 2009 | 8894 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2006 | 3200 | 0.040 |
Why?
|
| Celiac Disease | 1 | 2008 | 820 | 0.040 |
Why?
|
| Diphosphonates | 1 | 2004 | 634 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 3492 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1095 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2003 | 651 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2006 | 4300 | 0.040 |
Why?
|
| Piperidines | 1 | 2007 | 1667 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 4076 | 0.040 |
Why?
|
| Pyridines | 2 | 2007 | 2895 | 0.040 |
Why?
|
| Pyridones | 1 | 2002 | 819 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13594 | 0.030 |
Why?
|
| Palliative Care | 1 | 2012 | 3644 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 2003 | 747 | 0.030 |
Why?
|
| Rats | 6 | 2014 | 23786 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2017 | 216 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2003 | 1189 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 26395 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 6673 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 417 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 3782 | 0.030 |
Why?
|
| Opioid Peptides | 1 | 2014 | 37 | 0.030 |
Why?
|
| Disease Progression | 4 | 2017 | 13674 | 0.030 |
Why?
|
| Consensus | 2 | 2016 | 3214 | 0.030 |
Why?
|
| Kyphosis | 1 | 2017 | 253 | 0.030 |
Why?
|
| Feeding Behavior | 2 | 2005 | 3205 | 0.030 |
Why?
|
| Utilization Review | 1 | 2016 | 384 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8559 | 0.030 |
Why?
|
| Lipids | 1 | 2005 | 3345 | 0.030 |
Why?
|
| Body Composition | 1 | 2003 | 2462 | 0.030 |
Why?
|
| Contrast Media | 2 | 2017 | 5334 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 4045 | 0.030 |
Why?
|
| Naltrexone | 2 | 2007 | 319 | 0.030 |
Why?
|
| Incidence | 1 | 2012 | 21547 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 2913 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3412 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6512 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6962 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2006 | 8748 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3928 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 1642 | 0.030 |
Why?
|
| Rats, Long-Evans | 2 | 2003 | 380 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2003 | 466 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 6320 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2011 | 41808 | 0.020 |
Why?
|
| Narcotic Antagonists | 2 | 2007 | 591 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 6856 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2003 | 2294 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 699 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2013 | 489 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 590 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 6214 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 625 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4978 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2015 | 734 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 140 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 328 | 0.020 |
Why?
|
| Motor Activity | 2 | 2014 | 2713 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2921 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 1793 | 0.020 |
Why?
|
| Melanoma | 2 | 2004 | 5709 | 0.020 |
Why?
|
| Coccyx | 1 | 2007 | 13 | 0.020 |
Why?
|
| Reoperation | 1 | 1998 | 4342 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 1679 | 0.020 |
Why?
|
| Protein Binding | 2 | 2014 | 9344 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 10765 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 430 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 1399 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6346 | 0.020 |
Why?
|
| Research | 1 | 2015 | 1981 | 0.020 |
Why?
|
| Hypocalcemia | 1 | 2008 | 205 | 0.020 |
Why?
|
| Income | 1 | 2015 | 1879 | 0.020 |
Why?
|
| New York | 1 | 2009 | 884 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 412 | 0.020 |
Why?
|
| Maprotiline | 1 | 2005 | 3 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2014 | 1141 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1751 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3586 | 0.020 |
Why?
|
| Imipramine | 1 | 2005 | 98 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6547 | 0.020 |
Why?
|
| Pelvic Bones | 1 | 2008 | 274 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2016 | 2898 | 0.020 |
Why?
|
| Drinking | 1 | 2007 | 196 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 1189 | 0.020 |
Why?
|
| Steroids | 1 | 2010 | 938 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3554 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 365 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 74976 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5323 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3709 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2005 | 385 | 0.010 |
Why?
|
| Amino Acids | 1 | 2010 | 1716 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2725 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1798 | 0.010 |
Why?
|
| Length of Stay | 1 | 1998 | 6526 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 5864 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2024 | 26428 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 4862 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 17591 | 0.010 |
Why?
|
| Thigh | 1 | 2005 | 239 | 0.010 |
Why?
|
| Mesna | 1 | 2003 | 62 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7861 | 0.010 |
Why?
|
| CHO Cells | 1 | 2006 | 1379 | 0.010 |
Why?
|
| Chlordiazepoxide | 1 | 2002 | 42 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2003 | 233 | 0.010 |
Why?
|
| Flumazenil | 1 | 2002 | 84 | 0.010 |
Why?
|
| Pentylenetetrazole | 1 | 2002 | 72 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 3956 | 0.010 |
Why?
|
| Convulsants | 1 | 2002 | 70 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 396 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 491 | 0.010 |
Why?
|
| GABA Modulators | 1 | 2002 | 109 | 0.010 |
Why?
|
| Animals | 7 | 2014 | 169335 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2423 | 0.010 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2003 | 131 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11886 | 0.010 |
Why?
|
| Shoulder Pain | 1 | 2003 | 152 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2015 | 24333 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7478 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2005 | 733 | 0.010 |
Why?
|
| Lorazepam | 1 | 2002 | 155 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2002 | 163 | 0.010 |
Why?
|
| Saimiri | 1 | 2002 | 337 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 1885 | 0.010 |
Why?
|
| Pain | 2 | 2008 | 5100 | 0.010 |
Why?
|
| Binding Sites | 1 | 2010 | 6023 | 0.010 |
Why?
|
| Viral Load | 1 | 2010 | 3398 | 0.010 |
Why?
|
| Medicine | 1 | 2009 | 947 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2006 | 949 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5404 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18354 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2003 | 559 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 1196 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2015 | 8094 | 0.010 |
Why?
|
| Anxiety | 1 | 2014 | 4672 | 0.010 |
Why?
|
| Seizures | 2 | 2002 | 3000 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 6901 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3968 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 1034 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 2008 | 1388 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 3080 | 0.010 |
Why?
|
| Receptors, GABA-A | 1 | 2002 | 625 | 0.010 |
Why?
|
| Conscious Sedation | 1 | 2002 | 534 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1418 | 0.010 |
Why?
|
| Postural Balance | 1 | 2002 | 639 | 0.010 |
Why?
|
| Mice | 4 | 2006 | 82072 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2002 | 864 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 4651 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 2234 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 1610 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1506 | 0.010 |
Why?
|
| Ethanol | 1 | 2002 | 1331 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 7245 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 12095 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6131 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2002 | 1862 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15951 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 10115 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 2493 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 9384 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2003 | 2909 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2003 | 3335 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 30046 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12801 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 16053 | 0.010 |
Why?
|
| Computational Biology | 1 | 2003 | 3562 | 0.010 |
Why?
|
| Survival Rate | 1 | 2004 | 12873 | 0.010 |
Why?
|
| Sleep | 1 | 2002 | 4820 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 5831 | 0.000 |
Why?
|